Acurx Pharmaceuticals Inc (ACXP)

[gfp927z]

>> price tag <<

I figure it should be a big number, considering that ACXP's drug will likely become the new standard treatment for C. Dif, and the market is so huge --> 500,000 cases of C. Dif in the US per year, and 20,000 deaths. So the acquisition price tag can be many multiples of ACXP's current $75 mil market cap. We should get the full unblinded Phase 2b details soon, although we already know that clinically the results were excellent. While the bio sector is full of surprises, logic says that ACXP should be a big winner, so we'll see what happens :o)



---